CPT code 87636 – SARS-CoV-2, influenza A and B multiplex NAAT

Key takeaways

CPT code 87636 reports one multiplex NAAT that detects SARS-CoV-2, influenza A and influenza B from a single specimen.

Use 87637 when the panel also reports RSV, and 87635 when the NAAT targets SARS-CoV-2 alone.

Medicare pays 87636 under the Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule. Rates normalized after the PHE ended on May 11, 2023.

Most 87636 denials come from four errors: an antigen test billed as a NAAT, the wrong sibling code, no QW modifier or no CLIA number.

Pabau’s claims management software pre-fills claims from the patient record, checks required fields and submits them through Claim.MD, with eligibility checks and remittance posting.

CPT code 87636 covers one NAAT run for COVID-19 and both flu types

CPT code 87636 reports a single multiplex molecular test that detects SARS-CoV-2, influenza A and influenza B from one specimen. The lab amplifies nucleic acid for all three viruses in the same run, so one code covers the whole panel.

The AMA CPT Editorial Panel places 87636 under the parent heading Infectious agent detection by nucleic acid (DNA or RNA). Its own descriptor reads: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique.

That puts it in the 87471-87801 infectious agent detection by nucleic acid (DNA or RNA) range, within Microbiology (87001-87999).

The AMA created the code during the COVID-19 public health emergency (PHE) for panels that test for SARS-CoV-2 and seasonal flu together. It stayed active and billable after the PHE ended on May 11, 2023.

What the lab must run and report to support 87636

Four conditions have to hold before 87636 fits. The first is the method. The instrument must use an amplified probe technique, such as PCR, and antigen platforms don’t qualify however fast they are.

• Specimen types: Nasopharyngeal, nasal and mid-turbinate swabs are the most common specimens. Many payers also accept an anterior nasal swab collected per the instrument’s labeling.
• Setting: The test can run in a clinical lab or at the point of care (POC). A POC instrument needs a CLIA waiver for that use. Not every payer pays 87636 in POC settings, so check the payer’s lab policy first.
• One reaction: All three targets must come from the same specimen in the same multiplex run. Running three single-target tests and billing 87636 is miscoding.
• Every result reported: The report must show a result for each target, whether positive, negative or indeterminate. A report with only two results doesn’t support 87636.

87636, 87637, 87635 or 87811: The targets decide the code

Each sibling code maps to a set of targets and a detection method. Choosing by assay brand rather than by the analytes detected is a coding error that payers deny. The tree below shows the two questions that settle the choice.

87636 vs. 87811: These codes describe different technologies. 87636 requires molecular amplification, while 87811 detects SARS-CoV-2 antigen protein directly. Billing 87636 for a rapid antigen reader is a method mismatch that audits catch easily, because the device’s CLIA listing shows its method. The AAPC CPT code lookup has the full descriptors side by side.

87636 vs. 87637: If the panel also detects RSV and the lab reports an RSV result, bill 87637 instead. Billing 87636 for a four-target report undercodes the service. Billing 87637 when RSV wasn’t a reported target is upcoding.

ICD-10 pairings that support medical necessity for 87636

Payers judge 87636 largely on the diagnosis code sent with it, and a missing or unsupported diagnosis is a common denial trigger. Each payer’s Local Coverage Determination (LCD) may limit which ICD-10-CM codes it accepts. Check the payer’s published policy before you rely on a pairing.

When all three targets come back negative, code the reason for testing instead of a confirmed disease. That might be a symptom such as R05.9, an exposure code or a screening code. Some Medicare Administrative Contractors (MACs) deny U07.1 on a negative result, because the lab report doesn’t support it.

How Medicare pays 87636 under the lab fee schedule

Medicare pays 87636 under the CMS Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule. CLFS codes are paid at the lesser of the billed charge or the national limitation amount. Most carry no geographic adjustment.

During the PHE, CMS paid emergency-era rates for multiplex COVID tests that ran well above standard CLFS pricing. Those rates expired when the PHE ended on May 11, 2023, and 87636 moved to standard CLFS pricing. Practices still budgeting at emergency rates saw revenue per claim drop.

CMS updates the CLFS every year, and new rates take effect on January 1. To check the current rate, download the CLFS data file from the CMS Clinical Laboratory Fee Schedule page. Find 87636, note the national limitation amount for the calendar year, and confirm any local instructions with your MAC.

Commercial rates may sit at, above or below the CLFS, so don’t assume they mirror Medicare. Ask your payer’s provider relations contact for its current lab fee schedule.

Modifiers for 87636: QW for waived tests, 59 only when distinct

Modifier choice for 87636 depends on where the test ran and which other lab codes share the claim. A wrong or missing modifier is a common denial trigger, so confirm the combination with your clearinghouse before you submit.

• Modifier QW (CLIA-waived): Required when 87636 is billed from a CLIA-waived point-of-care instrument. The facility needs a Certificate of Waiver covering that assay. Leaving QW off a POC claim to Medicare typically triggers a technical denial. Adding QW to a non-waived lab test is incorrect and can cause a denial or audit query.
• Modifier 59 (distinct procedural service): Use it only when 87636 and another lab code on the same date are separate services. That means a separate specimen or a separate indication. It doesn’t override a bundling edit when both codes target the same analytes from one run. Document the distinct clinical basis first.
• Modifier SC (medically necessary): Some payers ask for SC to show the test was ordered for medical necessity rather than convenience. Not all payers recognize it, so check each payer’s policy before adding it.
• No modifier: When a non-waived lab runs 87636 and it’s the only respiratory panel on the claim, Medicare doesn’t routinely require a modifier. A specific LCD may say otherwise.

Your CLIA certificate decides whether QW applies

The facility’s CLIA certificate sets both where the test can run and which modifier applies. A Certificate of Waiver permits waived tests only. A Certificate of Compliance or Accreditation permits moderate- and high-complexity testing.

Run 87636 on a waived instrument at a waiver-certified site, and QW is mandatory on the Medicare claim. Run the same assay in a full-service lab under a Certificate of Compliance, and QW doesn’t apply.

Documentation that holds up when a payer audits 87636

Post-PHE audits of COVID testing codes have increased. Records that went unchallenged during the emergency are now grounds for denial and recoupment. Complete documentation is what turns an 87636 test into a clean claim.

• Ordering provider: The record and the claim must show the ordering provider’s name and NPI. An order can’t be attributed to a facility without an individual provider.
• Clinical indication: Record why the test was ordered, such as symptoms, a known exposure, pre-procedure screening or a public health directive. The ICD-10 code on the claim must match that reason.
• Specimen details: Record the specimen type, collection date and collector. The collection date must match the date of service on the claim.
• Instrument and method: The lab report or instrument log must confirm a NAAT method. Naming the assay adds a useful audit trail.
• All three results: The final report must include results for SARS-CoV-2, influenza A and influenza B. A missing result undermines the 87636 descriptor.
• CLIA certificate number: The lab’s CLIA number must appear on the claim. It goes in Box 23 of the CMS-1500 / Loop 2300 REF (X4) segment of the 837P. A missing CLIA number is an automatic technical denial.

Electronic claims carry that number inside the 837 file your clearinghouse sends. A blank field in the record becomes a blank segment on the claim.

How an 87636 claim moves from swab to payment

Following one claim from start to finish shows where problems creep in. Here’s the usual path for a patient with symptoms who is tested in-house.

1. Order: The provider orders the panel and records the symptoms or exposure behind it.
2. Collection: Staff collect the swab and log the specimen type, date and collector.
3. Testing: The NAAT instrument runs all three targets in one reaction and reports each result.
4. Coding: The coder checks the targets on the report, picks 87636 and adds the diagnosis that matches the result and the order.
5. Claim build: The claim gets the CLIA number, QW if the test is waived, and one unit of 87636.
6. Submission: The clearinghouse checks the file format and forwards the claim to the payer.
7. Payment: The payer applies its fee schedule and returns a remittance advice with the paid amount or a denial reason.

Here’s the coding step in practice. A patient arrives with fever and cough, and the panel returns flu A positive, with SARS-CoV-2 and flu B negative. The claim carries 87636 with J10.1, because the panel identified a seasonal flu virus.

Before you submit an 87636 claim, run this six-point check

Each line below maps to a denial reason in the next section. Tick all six and the claim is ready to go.

• The instrument is a NAAT, not an antigen reader.
• The report shows exactly three results: SARS-CoV-2, flu A and flu B.
• The diagnosis code matches the documented reason for testing and the payer’s LCD.
• The CLIA number is on the claim, and the certificate is current.
• QW is present for a waived POC test and absent for a non-waived lab test.
• No 87635, 87637 or single-target flu code sits on the claim for the same specimen.

Why 87636 claims get denied, and the fix for each

Most 87636 denials follow a handful of repeatable patterns. Sorting rejections by root cause before you resubmit is the core of denial management.

• Method mismatch: An antigen test was billed as 87636, and auditors checked the device’s CLIA listing. Fix: make sure billing staff know which platforms are NAAT.
• Wrong sibling code: 87636 was billed for a panel that reported RSV (use 87637) or for SARS-CoV-2 alone (use 87635). Fix: tie code choice to the targets on the report, not the assay brand.
• Unsupported diagnosis: The diagnosis doesn’t meet the payer’s medical necessity rules. One example is screening code Z11.59 on a patient with symptoms, where the LCD expects the symptom codes. Fix: check the MAC’s LCD for respiratory molecular testing before you submit.
• Missing or invalid CLIA number: Box 23 is blank or holds an expired certificate number. Fix: keep a tracker of CLIA certificates and renewal dates.
• QW missing on a POC claim: A waived POC instrument was used, but QW wasn’t appended. Fix: set your billing system to add QW when the POC lab location is selected.
• Duplicate billing: A second claim for 87636, or for 87635, went out for the same patient, date and specimen. Fix: run a same-day duplicate check before submission.
• Frequency limits: Some payers cap how many 87636 tests they pay in a rolling period. Fix: build each payer’s frequency limits into your pre-submission review.

Bundling rules: What can’t be billed alongside 87636

The National Correct Coding Initiative (NCCI) sets bundling edits that stop component codes being billed when a comprehensive code covers the service. For 87636, the principle is simple. You can’t unbundle a multiplex panel and bill each target separately. Claims management software that validates required claim fields before submission helps clean claims get through.

• No 87636 + 87635 from the same specimen: 87635 is already included in the 87636 panel, so billing both from one run is unbundling. The NCCI edit applies with or without modifier 59, unless a separate, medically distinct specimen was collected.
• No 87636 + single-target codes from the same run: Billing individual infectious-agent codes alongside 87636 for analytes from the same reaction is an NCCI violation. Examples include 87486 for Chlamydia pneumoniae and 87501 for influenza virus, each type or subtype.
• No 87636 + 87637 from the same specimen: The two codes cover overlapping targets. Billing both from one specimen is upcoding.
• Modifier 59 doesn’t override identical services: It’s valid only when a separate, distinct service took place. Using it to push past an edit between codes for the same targets is upcoding, and it exposes the practice to recoupment.

Modifier 59 can legitimately apply when a patient gets an 87636 panel and a separate test on the same day. The second test needs a different specimen or a different clinical purpose. The record must show both the separate indication and the separate collection.

How claims software keeps 87636 claims complete before they reach the payer

Most of the fixes above are manual checks: the right code, the matching diagnosis, the CLIA number and the QW modifier. In a busy practice, those checks often happen at the end of the day, from memory, across several screens.

Pabau, the practice management and billing platform we build, moves that work into the patient record. The claim form pre-fills from the visit, so the CPT code and diagnoses already recorded land on the claim. Built-in CPT and ICD-10 lookup libraries help staff find codes quickly. The claim can’t be sent until its required fields are complete.

In the US, claims go out electronically through the Claim.MD clearinghouse, which also handles eligibility checks and remittance posting. Fewer claims bounce back for missing data, so your team spends less time chasing them.

Send cleaner lab claims with Pabau

Pabau pre-fills claims from the patient record, validates required fields, and submits them through Claim.MD with eligibility checks and remittance posting. Your CPT 87636 claims reach payers complete.

Book a demo

Conclusion

CPT 87636 is a narrow code, and that works in your favor. Once the method and the three targets are confirmed, the code choice is settled. The denials that remain are predictable, and each one has a fix you can build into the workflow.

Start with the two checks that cost the most when missed: the method on the instrument and the CLIA number on the claim. Then pull the new CLFS file each January, so your expected payment matches what Medicare pays.

Pabau handles the claim side of that routine. It pre-fills claims from the record, checks required fields and submits them through Claim.MD. Book a demo to see how your 87636 claims can go out complete the first time.

Continue your research

Testing patients with no symptoms? ICD-10 code Z11.59 explains when the viral screening code supports a test like 87636.

Running a rapid flu antigen test instead? CPT code 87804 covers billing and reimbursement for antigen-based influenza testing.

Want to understand how denial patterns are tracked across codes? Denial codes in medical billing covers CARC and RARC code interpretation to speed up appeals.

Preparing for post-PHE audits? Medical billing compliance walks through the laws and violations behind lab claim recoupments.

Looking for the full billing picture? What is revenue cycle management explains the end-to-end process from lab order through payment posting.

Frequently asked questions